Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

N-myristoyltransferase 1 Inhibitors

N-myristoyltransferase 1 (NMT1) inhibitors represent a class of chemical compounds designed to target and inhibit the enzymatic activity of N-myristoyltransferase 1, an essential enzyme responsible for the covalent attachment of myristic acid to the N-terminal glycine of substrate proteins. This post-translational modification, known as N-myristoylation, plays a critical role in regulating the localization, stability, and function of a diverse range of proteins, particularly those involved in signaling pathways, cell growth, and cellular differentiation. NMT1, as one of two N-myristoyltransferase isoforms, catalyzes the transfer of the 14-carbon fatty acid (myristate) from myristoyl-coenzyme A (myristoyl-CoA) to the protein substrate, facilitating its membrane association and influencing its functional activity within cellular environments. Inhibiting NMT1 interrupts this process, impacting the overall protein functionality and altering cellular processes such as signal transduction and protein-protein interactions.

Structurally, NMT1 inhibitors are often characterized by their ability to bind competitively to the active site of the enzyme, preventing the binding of myristoyl-CoA or the substrate protein. These inhibitors generally possess hydrophobic regions that mimic the fatty acyl chain of myristic acid, allowing them to interact favorably with the enzyme's substrate-binding pocket. Additionally, many of these inhibitors include polar moieties or specific functional groups that enhance binding affinity through hydrogen bonding or ionic interactions with residues in the active site. Some of these inhibitors are highly selective for NMT1 over its isoform NMT2, providing a targeted approach for studying the specific biological pathways regulated by NMT1. The development and optimization of NMT1 inhibitors involve detailed structure-activity relationship (SAR) studies to fine-tune their binding properties and inhibitory efficacy, making them valuable tools for probing the biochemical mechanisms involving NMT1-catalyzed protein modifications.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Oleic Acid

112-80-1sc-200797C
sc-200797
sc-200797A
sc-200797B
1 g
10 g
100 g
250 g
$36.00
$102.00
$569.00
$1173.00
10
(1)

This fatty acid analog may disrupt cellular lipid rafts, potentially decreasing NMT1's access to its myristoyl-CoA substrate due to altered membrane dynamics.

Cerulenin (synthetic)

17397-89-6sc-200827
sc-200827A
sc-200827B
5 mg
10 mg
50 mg
$158.00
$306.00
$1186.00
9
(1)

Cerulenin could inhibit fatty acid synthesis, leading to a depletion of myristoyl-CoA levels and a subsequent decrease in NMT1 activity.

Tipifarnib

192185-72-1sc-364637
10 mg
$720.00
(0)

Although a farnesyltransferase inhibitor, Tipifarnib might cross-inhibit NMT1 due to similarities in the enzymes' active sites, leading to reduced activity.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$36.00
$68.00
$107.00
$214.00
$234.00
$862.00
$1968.00
47
(1)

Curcumin may downregulate NMT1 expression by altering the transcriptional machinery or signaling pathways that control the NMT1 gene.

rac Perhexiline Maleate

6724-53-4sc-460183
10 mg
$184.00
(0)

By inhibiting mitochondrial carnitine palmitoyltransferase, Perhexiline might decrease the pool of fatty acids available for myristoylation by NMT1.

Manumycin A

52665-74-4sc-200857
sc-200857A
1 mg
5 mg
$215.00
$622.00
5
(1)

Manumycin A could inhibit NMT1 indirectly by inhibiting the synthesis of isoprenoid precursors necessary for myristoyl-CoA synthesis.

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
$28.00
$88.00
$332.00
12
(1)

Lovastatin could lead to a decrease in NMT1 activity by inhibiting HMG-CoA reductase, thus reducing the levels of myristic acid and myristoyl-CoA.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib could indirectly downregulate NMT1 expression by inhibiting multiple kinases involved in signaling pathways that control protein synthesis and turnover.